Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

Medical University of Vienna logo

Medical University of Vienna

Status

Unknown

Conditions

Evidence of Liver Transplantation

Study type

Observational

Funder types

Other

Identifiers

NCT02695979
1458/2014

Details and patient eligibility

About

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Full description

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Enrollment

100 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion criteria

  • Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Trial design

100 participants in 1 patient group

Patients undergoing OLT
Description:
Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems